Intract Pharma
Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system.
Contact Intract Pharma via their website
News archive
22/04/2021 Intract Pharma and NIBEC Enter into an Agreement to Develop Ulcerative Colitis Treatment...more
01/04/2021 Intract Pharma Enters into Research Collaboration with Ferring Pharmaceuticals...more
20/08/2020 Intract Pharma Limited and Celltrion Group announce collaboration...more
26/05/2020 Intract Pharma and N&S Pharmacy Investment announce partnership...more
05/05/2020 Intract Pharma and Elasmogen Ltd announce collaboration...more
24/10/2019 Intract’s Soteria® and Phloral® Highlighted Among Revolutionary Delivery Approaches...more
07/05/2019 Carus Animal Health and Intract Pharma Announce Drug Delivery partnership...more
05/04/2019 Intract Pharma and Neopharma Japan Enter Collaborate to Develop GI Novel Treatment...more
27/03/2019 Intract Pharma announces market launch of Phloral® colon-targeting product...more
28/11/2018 Intract Pharma nominated for Genesis 2018 BioNewsRound Award...more
22/03/2018 Intract Pharma joins the BioPartner programme...more
